Prosecution Insights
Last updated: November 20, 2026
Application No. 18/671,086

MIXED MODE SUBTRACTIVE ANION EXCHANGE CHROMATOGRAPHY LIGANDS BASED ON 4-(2-(DIMETHYLAMINO)ETHOXY)ANILINE STRUCTURES

Non-Final OA §102§103
Filed
May 22, 2024
Priority
May 22, 2023 — provisional 63/503,496
Examiner
SODERQUIST, ARLEN
Art Unit
1797
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Bio-Rad Laboratories Inc.
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
9m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
561 granted / 936 resolved
-5.1% vs TC avg
Strong +26% interview lift
Without
With
+26.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
23 currently pending
Career history
962
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
43.0%
+3.0% vs TC avg
§102
15.0%
-25.0% vs TC avg
§112
32.0%
-8.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 936 resolved cases

Office Action

§102 §103
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-4 and 7 are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by Wang (CN 109972991). On page 2 of the patent publication Wang teaches the following 2 compounds. PNG media_image1.png 200 400 media_image1.png Greyscale These two compounds are anticipatory of the structure found in claims 1-2. The first structure is also anticipatory of claims 3-4 and 7. Claims 1-4 and 7 are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by Liu (Dyes and Pigments 2007). Figure 2of Liu shows the synthesis of sone dyes. In the synthesis Compound 7, PNG media_image2.png 200 400 media_image2.png Greyscale , in which n = 3 and 8 is anticipatory of the structures found in claims 1-2. When n = 3, the structure is also anticipatory of claims 3-4 and 7. Claims 1 and 6-7 are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by Jefferies (US 3,839,426). With respect to claim 1, Column 24, line 44 to column 26, line 31 teach the synthesis of 4 different quaternary ammonium chlorides. Column 26, lines 23-31 teach that in addition to those for which detailed preparations are given, the following quaternary ammonium intermediates are obtained when the indicated nitrophenyl-substituted quaternizing agent is interacted with the indicated tertiary amino compound. Of relevance to the instant claims is column 26, lines 69-71 teaching N-Methyl-N-isobutyl-N-3-hydroxybutyl-N-4-aminobenxylarmmonium iodide starting with N-3-hydroxybutyl- N-isobutylmethylamine and 4-nitrobenzyl iodide. The N-Methyl-N-isobutyl-N-3-hydroxybutyl-N-4-aminobenxylarmmonium iodide is anticipatory of claims 1 and 6-7. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 5, 7 and 10 are rejected under 35 U.S.C. 103 as being unpatentable over Wang or Liu as applied to claims 1-2 above, and further in view of Soleimani-Gorgani. The compounds of Wan and Liu are used in the synthesis of cationic dyes containing at least one azo group. Wang and Liu do not teach that the R groups are the same and are a methyl group or an ethyl group. In the paper Soleimani-Gorgani teaches cationic reactive dyes for nylon. Table 1 on page 611 shows the dye structures. Schemes 1 and 2 on page 612 show different methods of synthesizing a m-aminophenyltrimethylammonium salt. Scheme 3 in the same page shows the use of the m-aminophenyltrimethylammonium salt to form one of the dyes. With respect to claim 5, it would have been obvious to one of ordinary skill in the art at the time the application was filed to substitute the trimethylammonium salt structure Soleimani-Gorgani for the propyldimethyl ammonium salt structures used by Wang or Liu because the salt structure of Soleimani-Gorgani is similar to the salt structure of Wang and Liu and is being used for the same purpose in the dyes of Liu, Soleimani-Gorgani and Wang providing an expectation that the substitution would perform the same function when incorporated into the Liu and Wang dyes. With respect to claim 7, its scope includes the structure of claim 5 so that the obviousness of claim 5 extends to claim 7. With respect to claim 10, the proposed substitution into the Wang compound would produce compound CB467b so that claim 10 is obvious for the reasons given above for claim 5. Additionally with respect to claim 10the proposed substitution into the Liu compound would produce compound CB466x so that claim 10 is also obvious for the reasons given above for claim 5. Claims 11-20 are allowed. Claims 8-9 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: the art of record fails to teach or fairly suggest the required structure of the compounds of claims 8-9 or the mixed mode chromatography medium of claim 11. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The additionally cited art relates to structure similar to the above applied references. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arlen Soderquist whose telephone number is (571)272-1265. The examiner can normally be reached 1st week Monday-Thursday, 2nd week Monday-Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lyle Alexander can be reached at (571)272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ARLEN SODERQUIST/ Primary Examiner, Art Unit 1797
Read full office action

Prosecution Timeline

May 22, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12800507
BIOLOGICAL SAMPLE ANALYSIS DEVICE AND BIOLOGICAL SAMPLE ANALYSIS METHOD
4y 12m to grant Granted Nov 17, 2026
Patent 12800529
LIGAND-TARGET INTERACTION ANALYSIS BY PHOTOCHEMICALLY INDUCED DYNAMIC NUCLEAR POLARIZATION (PHOTO-CIDNP) ENHANCED NMR SPECTROSCOPY
2y 9m to grant Granted Nov 17, 2026
Patent 12791395
DESCENDING AND ASCENDING TEMPERATURE INDICATORS UTILIZING DEEP EUTECTICS
4y 6m to grant Granted Nov 10, 2026
Patent 12791451
AUTOMATED WORKSTATION, AND PROCESS, FOR HANDLING HISTOLOGICAL SAMPLES IN THE EMBEDDING STEP
2y 11m to grant Granted Nov 10, 2026
Patent 12782301
METHODS AND COMPOSITIONS FOR LOW SALINITY ENHANCED OIL RECOVERY
3y 5m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
86%
With Interview (+26.1%)
3y 3m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 936 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month